Progestin-only contraceptives used during breastfeeding transfer only tiny amounts of hormone into breast milk, and decades of research have not found harmful effects on infant growth, health, or development. The story is more nuanced than that one-liner, though, because progesterone plays a dual role in the breastfeeding relationship: the natural drop in progesterone after birth is what kickstarts milk production in the first place, and the synthetic progestins in contraceptives behave differently from the hormone your body makes on its own.
Why Progesterone Matters for Milk Production
During pregnancy, progesterone levels stay high. That elevated progesterone actually suppresses your body’s ability to produce mature breast milk, even though breast tissue is growing and preparing for lactation the entire time. It is only after you deliver the placenta that progesterone drops sharply, and that rapid withdrawal is the signal your body needs to begin producing milk in volume.1Advances in Nutrition. Causes of Low Milk Supply: The Roles of Estrogens, Progesterone, and Related External Factors The sudden absence of progesterone triggers a cascade of events, including the activation of prolactin receptors and the tightening of cell junctions in breast tissue, both of which are required for copious milk flow.
This is why there is sometimes anxiety about reintroducing a progesterone-like hormone through contraception while breastfeeding. If high progesterone kept milk production suppressed during pregnancy, could adding progestin back into your system undermine your supply? It is a reasonable concern, but the answer from clinical studies has been consistently reassuring for progestin-only methods.
How Much Progestin Actually Reaches the Baby
When you take a progestin-only pill or receive an injectable or implant, small quantities of the synthetic hormone do appear in breast milk. The amounts vary by formulation, but they are consistently very low relative to the maternal dose. For desogestrel (a common progestin-only pill), the drug’s active metabolite shows up in milk at a milk-to-plasma ratio of roughly 0.37 to 0.55, and a breastfed infant might ingest somewhere between 0.01 and 0.05 milligrams per day based on typical milk intake.2PubMed Central. Safety of Progestogen Hormonal Contraceptive Methods during Lactation: An Overview
For drospirenone, another progestin used in some contraceptives, a study of lactating women found that after a single dose, the average amount transferred into breast milk over 24 hours was about 635 nanograms, or roughly 0.02% of the mother’s dose. Assuming a baby drinks about 800 milliliters of milk per day, the estimated daily infant exposure comes out to around 3 micrograms.3PubMed. Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women That is a vanishingly small fraction of the adult therapeutic dose.
Other progestins follow a similar pattern. The injectable progestin ST-1435, for instance, was measured at an average milk-to-plasma ratio of 0.60, with actual milk concentrations in the range of picograms per milliliter, meaning trace amounts far below any level expected to produce a biological effect in the infant.4PubMed. Milk and plasma concentrations of the progestin ST-1435 in women treated parenterally with ST-1435 Even progesterone antagonists (a different class of drug) have shown very low passage into breast milk in primate studies.5Human Reproduction. Progesterone antagonist RU 486 accommodates but does not induce labour and delivery in primates
The takeaway from the pharmacokinetic data is that regardless of which progestin formulation a breastfeeding parent uses, the infant’s actual exposure through milk is extremely small, typically well under 1% of the weight-adjusted maternal dose.
What the Evidence Shows About Infant Growth
The question that matters most to parents is whether those small exposures translate into any measurable effect on their baby. On the question of growth, the evidence is extensive and consistent. A Cochrane systematic review of hormonal contraception during breastfeeding found that none of the trials identified a significant difference in infant growth or weight attributable to hormonal contraception.6Cochrane Database of Systematic Reviews. Hormonal contraception for women dado breastfeeding
A large systematic review encompassing five randomized trials and 38 observational studies reached the same conclusion: no adverse effects of progestin-only methods on infant growth, health, or development from six months to six years of age.7PubMed. Progestogen-only contraceptive use among breastfeeding women: a systematic review An updated version of that review reaffirmed the findings, noting that the overall body of evidence fails to demonstrate restricted growth, health problems, or impaired development in infants.8PubMed Central. Progestogen-only contraceptive use among breastfeeding women: a systematic review
Individual trials back this up with concrete numbers. A randomized controlled trial comparing immediate postpartum placement of a levonorgestrel implant to delayed placement found that the mean change in infant weight from birth to six months was about 4,632 grams in the immediate group versus 4,407 grams in the delayed group, a difference that was not statistically significant.9PubMed Central. The effect of immediate postpartum levonorgestrel contraceptive implant use on breastfeeding and infant growth: a randomized controlled trial Another study looking at injectable progestogen given in the early postpartum period found that average gains in both height and weight were comparable between infants whose mothers received the injection and those who did not, all the way through six months.10PubMed Central. Impact of Injectable Progestogen Contraception in Early Puerperium on Lactation and Infant Health
Long-Term Development and Puberty
Growth in the first year is one thing, but parents also wonder about effects that might not show up until later. The largest study to address this followed children exposed to depot medroxyprogesterone acetate (DMPA, commonly known as the Depo-Provera shot) either during pregnancy or during breastfeeding, comparing over 1,200 exposed children to more than 1,100 unexposed controls. Cross-sectional weights and heights were similar between groups throughout childhood. The researchers did observe what initially looked like a slightly higher risk of short stature among the exposed group, but after adjusting for socioeconomic factors, that association disappeared.11Contraception. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation
The one finding of note was a modest delay in the onset of pubic hair growth among girls exposed to DMPA. But there were no significant effects on other markers of puberty, and the study’s overall conclusion was that DMPA use during pregnancy or breastfeeding does not adversely affect long-term growth and development.12Contraception. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation That slight delay in one pubertal marker has not been replicated in a way that would raise clinical concern, but it is worth knowing about as a data point.
Effects on Milk Supply and Composition
A common fear is that progestin-based contraceptives will tank your milk supply. The research tells a surprisingly positive story. A large WHO-sponsored trial compared combined oral contraceptives, progestin-only minipills, and non-hormonal methods. Women using combined pills (which contain both estrogen and progestin) experienced a roughly 42% decline in milk volume over 18 weeks, compared to only about 12% with progestin-only pills and 6% with non-hormonal controls.13Contraception. Effects of hormonal contraceptives on milk volume and infant growth: WHO Special Programme of Research and Development and Research Training in Human Reproduction The decline in the progestin-only group was modest and not statistically different from the natural decline seen in the control group.
A systematic review of randomized trials reached the same conclusion: progestin-only contraceptives did not inhibit lactation, while combined oral contraceptives caused a significant decline in breast milk volume by comparison.14PubMed. Hormonal contraception during lactation. systematic review of randomized controlled trials In fact, some studies have found that progestin-only methods may actually increase milk volume slightly, though the effect is small and not reliably seen across all trials.15PubMed. A review of the use of progestogen-only minipills for contraception during lactation
As for milk composition, a trial comparing a desogestrel-containing progestin-only pill to a copper IUD (a completely non-hormonal method) found no significant differences in the composition or quantity of breast milk between the two groups, and infant growth and development were comparable through age two and a half years.16PubMed. Comparative study of the effects of a progestogen-only pill containing desogestrel and an intrauterine contraceptive device in lactating women Milk protein content did not change meaningfully in studies of injectable progestins, either, though slight decreases were noted across all groups, including controls, likely due to dietary factors rather than the hormones themselves.17British Medical Journal. Injected Progestogen and Lactation
Why Combined Hormonal Contraceptives Are Different
The distinction between progestin-only and combined hormonal contraceptives (which add estrogen to the mix) matters a great deal here, and it is a source of frequent confusion. When people hear “hormonal birth control is bad for breastfeeding,” they are usually hearing about combined pills, patches, or rings that contain estrogen. Estrogen is the component that reliably suppresses milk production. A scoping review of clinical guidelines confirmed that progestin-only methods continue to be considered safe for breastfeeding patients, while the concerns about decreased milk supply apply primarily to combined hormonal methods.18PubMed. Breastfeeding and Hormonal Contraception: A Scoping Review of Clinical Guidelines, Professional Association Recommendations, and the Literature
This distinction is important because parents sometimes avoid all hormonal contraception during breastfeeding based on what is essentially a warning about estrogen, not progestin. If you have been told that hormonal birth control will hurt your supply, it is worth clarifying with your provider whether they mean combined methods specifically. The progestin-only options, which include the minipill, hormonal IUDs, implants, and the Depo-Provera shot, have a much cleaner track record during lactation.
Preterm Infants and Vulnerable Populations
One question that understandably causes extra worry is whether preterm or medically fragile babies might be more sensitive to progestins in breast milk. Until recently, most of the research focused on healthy, full-term infants. An updated systematic review published in 2025 specifically looked at this gap and found that newly identified studies are consistent with prior reviews in showing no adverse effects on breastfeeding outcomes or infant health, while also adding evidence for preterm infants.19BMJ Sexual & Reproductive Health. Progestogen-only contraception use during breastfeeding: an updated systematic review The certainty of that evidence ranged from very low to moderate depending on the outcome measured, so it is not ironclad. But the direction is reassuring: preterm babies in these studies did not fare worse when their mothers used progestin-only contraception.
That said, the research in vulnerable populations is thinner than the research in healthy term infants. If your baby was born very early or has metabolic challenges, it is reasonable to have a more detailed conversation with your pediatrician about timing and choice of contraception, even though the current data does not suggest a specific risk.
The Neonatal Jaundice Question
One area where older research raised a flag involves neonatal jaundice, the yellowing of a newborn’s skin caused by elevated bilirubin. A study of 182 newborns found that among bottle-fed infants, those whose mothers had previously used steroid contraceptives had slightly but significantly higher bilirubin levels. Interestingly, this finding did not show up among breastfed infants. Separately, infants whose mothers had received progestogen therapy during pregnancy had mean bilirubin levels higher than all other groups, occasionally reaching levels that needed clinical attention.20British Medical Journal. Effect on Neonatal Jaundice of Oestrogens and Progestogens Taken before and after Conception
An experimental study from the same era added a layer of complexity. When progesterone itself was given directly to newborns, it did not increase bilirubin levels. However, when progesterone was given to nursing mothers, the bilirubin levels of their breastfed infants did rise, likely because progesterone metabolites, rather than the parent hormone, were passing through milk and interfering with bilirubin processing in the infant’s liver.21Journal of Endocrinology. THE SIGNIFICANCE OF STEROID HORMONES FOR THE DEVELOPMENT OF HYPERBILIRUBINAEMIA AND ICTERUS IN THE NEWBORN INFANT These are older studies, and modern progestin-only contraceptives use different synthetic hormones at different doses than the regimens tested in those experiments. Still, the finding is a reminder that the very early neonatal period, especially the first few days of life when jaundice risk is highest, may warrant extra caution about the timing of hormonal contraception initiation.
Natural Progesterone in Breast Milk
It is easy to focus entirely on synthetic progestins from contraceptives and forget that breast milk naturally contains progesterone produced by the mother’s own body. Even without any contraceptive use, your milk has measurable levels of both estrogen and progesterone. A narrative review noted that despite the potential impact of these naturally occurring hormones on the infant, limited research has actually examined how endogenous breast milk progesterone affects infant growth and health.22PubMed Central / Elsevier. Oestrogens and progesterone in human milk and their effects on infant health outcomes: A narrative review
Levels of natural progesterone in breast milk vary from person to person and fluctuate over time. Maternal factors like body composition, menstrual cycle resumption, and dietary patterns all play a role. The fact that infants are already exposed to progesterone through milk regardless of contraceptive use provides some context for the tiny additional amounts that come from progestin-only contraceptives. The margin between natural background exposure and contraceptive-related exposure is not as dramatic as you might expect.
A Note on In Utero Exposure Versus Breastfeeding Exposure
When researching this topic, you may come across studies about hormonal contraceptive exposure during pregnancy (meaning the mother was taking contraceptives without knowing she was pregnant). It is important not to confuse that scenario with breastfeeding exposure. The fetus in the womb is in direct vascular contact with the mother and receives far higher concentrations of any circulating substance than a breastfed infant, who encounters only the small fraction of drug that makes it into milk and then through the infant’s own digestive system.
One cohort study found that in utero exposure to hormonal contraception, particularly non-oral progestin-only products, was associated with elevated mortality risk in offspring, with hazard ratios reaching roughly 2.9 for non-oral progestin-only products compared to children of mothers who had only used contraception before conceiving.23MDPI. In Utero Exposure to Hormonal Contraception and Mortality in Offspring with and without Cancer: A Nationwide Cohort Study That finding applies specifically to fetal development and should not be extrapolated to the breastfeeding context, where the exposure pathway and dose are fundamentally different. Conflating the two is one of the more common errors that fuels unnecessary fear about progestins and breastfeeding.
How Study Quality Shapes What We Know
Honesty about the evidence base matters here. While the overall direction of the research is reassuring, the quality of individual studies is mixed. The updated systematic reviews consistently describe the available evidence as ranging from poor to fair in methodological quality.24PubMed Central. Progestogen-only contraceptive use among breastfeeding women: a systematic review Many of the observational studies did not adequately control for confounders like socioeconomic status, maternal nutrition, or the reason a particular contraceptive was chosen. The randomized trials tend to be small, and long-term follow-up data on children is sparse.
What makes the overall picture still convincing is the consistency of the findings across different study designs, different progestin formulations, different countries, and different time periods. When dozens of studies using different methods all point in the same direction, the signal is likely real even if no single study is definitive. But researchers have been open about the need for better-designed trials, particularly ones that follow children for longer and measure subtler outcomes like neurodevelopment and metabolic health in childhood. The absence of detected harm is not the same as proof of zero effect, especially when the tools for detection have been relatively blunt.
For the practical question parents are asking, the evidence is strong enough that every major professional organization endorses progestin-only contraception during breastfeeding.25PubMed. Breastfeeding and Hormonal Contraception: A Scoping Review of Clinical Guidelines, Professional Association Recommendations, and the Literature That endorsement is not casual; it reflects the judgment that decades of data, even imperfect data, consistently show no harm to infants. If future higher-quality research does reveal a subtle effect, the existing evidence strongly suggests it would be small rather than clinically meaningful.